

Alejandro Marcel Hasslocher-Moreno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4995826/publications.pdf>

Version: 2024-02-01

76
papers

2,349
citations

304368

22
h-index

223531

46
g-index

79
all docs

79
docs citations

79
times ranked

2327
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative effects of a cardiovascular rehabilitation program on functional capacity in patients with chronic chagasic cardiomyopathy with or without heart failure. <i>Disability and Rehabilitation</i> , 2023, 45, 51-56.	0.9	4
2	Two-dimensional strain derived parameters provide independent predictors of progression to Chagas cardiomyopathy and mortality in patients with Chagas disease. <i>IJC Heart and Vasculature</i> , 2022, 38, 100955.	0.6	3
3	Re: "Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation". <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 1093.	1.4	1
4	Chagas disease mortality during the coronavirus disease 2019 pandemic: A Brazilian referral center experience. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2022, 55, e0562.	0.4	4
5	Selenium, TGF-Beta and Infectious Endemic Cardiopathy: Lessons from Benchwork to Clinical Application in Chagas Disease. <i>Biomolecules</i> , 2022, 12, 349.	1.8	4
6	Letters to the Editor: Indeterminate form of Chagas Disease: some immunological insights. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2022, 55, e07132021.	0.4	0
7	Impact of COVID-19 In-hospital Mortality in Chagas Disease Patients. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	1
8	Cost-effectiveness of an exercise-based cardiovascular rehabilitation program in patients with chronic Chagas cardiomyopathy in Brazil: An analysis from the PEACH study. <i>Tropical Medicine and International Health</i> , 2022, 27, 630-638.	1.0	1
9	Factors related to the discontinuation and mortality rates of a cardiac rehabilitation programme in patients with Chagas disease: a 6-year experience in a Brazilian tertiary centre. <i>Tropical Medicine and International Health</i> , 2021, 26, 355-365.	1.0	1
10	Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study. <i>EClinicalMedicine</i> , 2021, 31, 100694.	3.2	32
11	Prevalence of metabolic syndrome and associated factors among patients with chronic Chagas disease. <i>PLoS ONE</i> , 2021, 16, e0249116.	1.1	7
12	Disulfiram repurposing in the combined chemotherapy of Chagas disease. <i>Medicine, Case Reports and Study Protocols</i> , 2021, 2, e0110.	0.0	5
13	The Liver and the Hepatic Immune Response in <i>Trypanosoma cruzi</i> Infection, a Historical and Updated View. <i>Pathogens</i> , 2021, 10, 1074.	1.2	8
14	Serological reactivity against <i>T. cruzi</i> -derived antigens: Evaluation of their suitability for the assessment of response to treatment in chronic Chagas disease.. <i>Acta Tropica</i> , 2021, 221, 105990.	0.9	6
15	Clinical profile and mortality in patients with <i>T. cruzi</i> /HIV co-infection from the multicenter data base of the "Network for healthcare and study of <i>Trypanosoma cruzi</i> /HIV co-infection and other immunosuppression conditions". <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009809.	1.3	12
16	Effects of Selenium treatment on cardiac function in Chagas heart disease: Results from the STCC randomized Trial. <i>EClinicalMedicine</i> , 2021, 40, 101105.	3.2	11
17	Temporal changes in the clinical-epidemiological profile of patients with Chagas disease at a referral center in Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2021, 54, e00402021.	0.4	8
18	Indeterminate form of Chagas disease: historical, conceptual, clinical, and prognostic aspects. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2021, 54, e02542021.	0.4	8

#	ARTICLE	IF	CITATIONS
19	Blood culture positivity rate for <i>Trypanosoma cruzi</i> in patients with chronic Chagas disease differs among different clinical forms. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 720-725.	0.7	4
20	The Search for Biomarkers and Treatments in Chagas Disease: Insights From TGF-Beta Studies and Immunogenetics. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 767576.	1.8	8
21	Chagas heart disease: An overview of diagnosis, manifestations, treatment, and care. <i>World Journal of Cardiology</i> , 2021, 13, 654-675.	0.5	25
22	Left Atrial Structure and Function Predictors of New-Onset Atrial Fibrillation in Patients with Chagas Disease. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 1363-1374.e1.	1.2	13
23	Progression Rate from the Indeterminate Form to the Cardiac Form in Patients with Chronic Chagas Disease: Twenty-Two-Year Follow-Up in a Brazilian Urban Cohort. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 76.	0.9	16
24	Discussing the Score of Cardioembolic Ischemic Stroke in Chagas Disease. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 82.	0.9	6
25	Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008035.	1.3	26
26	Association between <i>Trypanosoma cruzi</i> DTU TcII and chronic Chagas disease clinical presentation and outcome in an urban cohort in Brazil. <i>PLoS ONE</i> , 2020, 15, e0243008.	1.1	12
27	Adverse drug events and the associated factors in patients with chronic Chagas disease. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20190443.	0.4	1
28	Title is missing!. , 2020, 15, e0243008.		0
29	Title is missing!. , 2020, 15, e0243008.		0
30	Title is missing!. , 2020, 15, e0243008.		0
31	Title is missing!. , 2020, 15, e0243008.		0
32	Title is missing!. , 2020, 15, e0243008.		0
33	Title is missing!. , 2020, 15, e0243008.		0
34	Agreement between upper endoscopy and esophagography in the diagnosis of megaesophagus in Chagas disease. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2019, 52, e20180258.	0.4	3
35	Benznidazole treatment safety: the MÃ©decins Sans FrontiÃ©res experience in a large cohort of Bolivian patients with Chagasâ€™ diseaseâ€™ authorsâ€™ response. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1115-1116.	1.3	2
36	Exploring the parasite load and molecular diversity of <i>Trypanosoma cruzi</i> in patients with chronic Chagas disease from different regions of Brazil. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006939.	1.3	44

#	ARTICLE	IF	CITATIONS
37	A protocol update for the Selenium Treatment and Chagasic Cardiomyopathy (STCC) trial. <i>Trials</i> , 2018, 19, 507.	0.7	9
38	Quality of life and associated factors in patients with chronic Chagas disease. <i>Tropical Medicine and International Health</i> , 2018, 23, 1213-1222.	1.0	16
39	Ageing with Chagas disease: an overview of an urban Brazilian cohort in Rio de Janeiro. <i>Parasites and Vectors</i> , 2018, 11, 354.	1.0	31
40	Course of serological tests in treated subjects with chronic <i>Trypanosoma cruzi</i> infection: A systematic review and meta-analysis of individual participant data. <i>International Journal of Infectious Diseases</i> , 2018, 73, 93-101.	1.5	27
41	Benznidazole treatment safety: the MÃ©decins Sans FrontiÃ¨res experience in a large cohort of Bolivian patients with Chagas' disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2596-2601.	1.3	31
42	Omega-3 supplementation on inflammatory markers in patients with chronic Chagas cardiomyopathy: a randomized clinical study. <i>Nutrition Journal</i> , 2017, 16, 36.	1.5	12
43	Evolution of anti- <i>Trypanosoma cruzi</i> antibody production in patients with chronic Chagas disease: Correlation between antibody titers and development of cardiac disease severity. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005796.	1.3	18
44	Reassessment of quality of life domains in patients with compensated Chagas heart failure after participating in a cardiac rehabilitation program. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2017, 50, 404-407.	0.4	15
45	<i>Trypanosoma cruzi</i> I genotype among isolates from patients with chronic Chagas disease followed at the Evandro Chagas National Institute of Infectious Diseases (FIOCRUZ, Brazil). <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2017, 50, 35-43.	0.4	5
46	Cardiac rehabilitation program in patients with Chagas heart failure: a single-arm pilot study. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2016, 49, 319-328.	0.4	30
47	Does my patient have chronic Chagas disease? Development and temporal validation of a diagnostic risk score. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2016, 49, 329-340.	0.4	7
48	2 nd Brazilian Consensus on Chagas Disease, 2015. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2016, 49, 3-60.	0.4	239
49	Effect of physical exercise training in patients with Chagas heart disease: study protocol for a randomized controlled trial (PEACH study). <i>Trials</i> , 2016, 17, 433.	0.7	11
50	Chagas heart disease in professional athletes from endemic countries: A notorious case calls attention for its identification and stratification. <i>International Journal of Cardiology</i> , 2016, 207, 115-116.	0.8	2
51	FIRST REPORT OF ACUTE CHAGAS DISEASE BY VECTOR TRANSMISSION IN RIO DE JANEIRO STATE, BRAZIL. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2015, 57, 361-364.	0.5	4
52	Development of a risk score to predict sudden death in patients with Chaga's heart disease. <i>International Journal of Cardiology</i> , 2015, 187, 700-704.	0.8	48
53	Selenium Treatment and Chagasic Cardiopathy (STCC): study protocol for a double-blind randomized controlled trial. <i>Trials</i> , 2014, 15, 388.	0.7	19
54	A Clinical Adverse Drug Reaction Prediction Model for Patients with Chagas Disease Treated with Benznidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6371-6377.	1.4	39

#	ARTICLE	IF	CITATIONS
55	Left Atrial and Left Ventricular Diastolic Function in Chronic Chagas Disease. <i>Journal of the American Society of Echocardiography</i> , 2013, 26, 1424-1433.	1.2	46
56	Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 379.	0.7	10
57	Predictive value of transforming growth factor- β 21 in Chagas disease: towards a biomarker surrogate of clinical outcome. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2013, 107, 518-525.	0.7	22
58	Sports Events and Acute Coronary Syndrome: Possible Confounding Factors and Bias. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 101, 474-5.	0.3	1
59	Atenção integral e eficiência no Laboratório de Pesquisa Clínica em Doenças de Chagas do Instituto de Pesquisa Clínica Evandro Chagas, 2009-2011. <i>Epidemiologia E Serviços De Saude: Revista Do Sistema Unico De Saude Do Brasil</i> , 2013, 22, 295-306.	0.3	1
60	Safety of benznidazole use in the treatment of chronic Chagas' disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1261-1266.	1.3	73
61	Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial. <i>Trials</i> , 2012, 13, 244.	0.7	15
62	Dealing with initial inconclusive serological results for chronic Chagas disease in clinical practice. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 965-974.	1.3	21
63	ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2010, 10, 337.	1.3	106
64	<i>Trypanosoma rangeli</i> Tejera, 1920, in chronic Chagas' disease patients under ambulatory care at the Evandro Chagas Clinical Research Institute (IPEC - Fiocruz, Brazil). <i>Parasitology Research</i> , 2008, 103, 697-703.	0.6	16
65	Estratégias de prevenção do acidente vascular encefálico cardioembólico na doença de Chagas. <i>Arquivos Brasileiros De Cardiologia</i> , 2008, 91, 306-310.	0.3	59
66	Development and Validation of a Risk Score for Predicting Death in Chagas' Heart Disease. <i>New England Journal of Medicine</i> , 2006, 355, 799-808.	13.9	523
67	T-wave axis deviation as an independent predictor of mortality in chronic Chagas' disease. <i>American Journal of Cardiology</i> , 2004, 93, 1136-1140.	0.7	34
68	Electrocardiographic Ventricular Repolarization Parameters in Chronic Chagas' Disease as Predictors of Asymptomatic Left Ventricular Systolic Dysfunction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 1326-1335.	0.5	20
69	Prognostic Value of QT Interval Parameters for Mortality Risk Stratification in Chagas' Disease. <i>Circulation</i> , 2003, 108, 305-312.	1.6	125
70	Implication of Transforming Growth Factor- β 21 in Chagas Disease Myocardiopathy. <i>Journal of Infectious Diseases</i> , 2002, 186, 1823-1828.	1.9	70
71	Progressive Chagas' cardiomyopathy is associated with low selenium levels.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 66, 706-712.	0.6	53
72	Chronic pulmonary histoplasmosis in the State of Rio de Janeiro, Brazil. <i>Mycopathologia</i> , 1999, 145, 75-79.	1.3	13

#	ARTICLE	IF	CITATIONS
73	Polymerase chain reaction detection of <i>Trypanosoma cruzi</i> in human blood samples as a tool for diagnosis and treatment evaluation. <i>Parasitology</i> , 1995, 110, 241-247.	0.7	156
74	Sensitivity and specificity of a rapid diagnostic test for chronic Chagas disease at a referral center in Brazil - can it be included as a standard serological diagnostic test in the clinical practice of a referral center?. <i>Microbes, Infection and Chemotherapy</i> , 0, 1, e1236.	0.0	0
75	The Saga of Selenium Treatment Investigation in Chagas Disease Cardiopathy: Translational Research in a Neglected Tropical Disease in Brazil. , 0, , .		0
76	Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning. , 0, , .		0